Matt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CFO Matt Zuga sold 13,235 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $24,352.40. Following the completion of the transaction, the chief financial officer now directly owns 198,210 shares of the company’s stock, valued at approximately $364,706.40. This trade represents a 6.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Acumen Pharmaceuticals Trading Down 1.1 %

Acumen Pharmaceuticals stock traded down $0.02 during trading on Tuesday, reaching $1.83. 184,478 shares of the company were exchanged, compared to its average volume of 247,994. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The stock’s 50 day simple moving average is $2.27 and its two-hundred day simple moving average is $2.52. The company has a market capitalization of $109.95 million, a P/E ratio of -1.33 and a beta of 0.02. Acumen Pharmaceuticals, Inc. has a 52-week low of $1.69 and a 52-week high of $5.09.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.14). During the same quarter last year, the firm earned ($0.24) EPS. On average, equities research analysts expect that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ABOS. SG Americas Securities LLC purchased a new stake in shares of Acumen Pharmaceuticals during the third quarter worth $44,000. American Century Companies Inc. grew its position in shares of Acumen Pharmaceuticals by 31.3% during the second quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock worth $110,000 after buying an additional 10,840 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Acumen Pharmaceuticals during the second quarter worth approximately $127,000. Murchinson Ltd. acquired a new stake in Acumen Pharmaceuticals in the second quarter valued at approximately $136,000. Finally, Barclays PLC lifted its stake in Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock worth $154,000 after acquiring an additional 40,551 shares during the last quarter. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, November 13th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.